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Summary Monoclonal antibody (McAb) Po66 has been obtained by immunisation of mice against a human
lung squamous cell carcinoma. The in vitro reactivity of the antibody with cancer cells and its ability to
localise in human lung cancer xenografts growing in nude mice have been reported earlier. Presented here is
the first clinical evaluation of the antibody for scintigraphic detection of tumours. Thirty-three patients with
histologically confirmed primary non-small cell lung carcinoma were investigated. Twenty-seven of them were
explored at the preoperative stage and six at 6 months after surgery. Biodistribution results were obtained
from seven operated patients by combining injections of '3'I-radiolabelled Po66 and of '251-labelled unrelated
immunoglobulin. The localisation index was three times higher for this specific antibody. Immunoscintigraphy
detected 78% of primary tumours and 100% of recurrences. In this short series of patients, immunoscinti-
graphy proved helpful in the assessment of tumour spread in four patients by visualising localisations in the
mediastinum or the contralateral lung which the CT scan had failed to demonstrate. Immunoscintigraphy was
also more efficient than plain chest X-ray for the detection of local tumour recurrences.
Radiolabelled monoclonal antibodies (McAbs) directed
against tumour antigens are potentially of great interest in
diagnosis and therapy of cancer. Such McAbs have already
been raised against a variety of human tumour-associated
antigens and have been used for scintigraphic detection of
cancers, e.g. colorectal carcinoma (Mach et al., 1987; Chatal
et al., 1984), pancreas carcinoma (Senekowitsch et al., 1985),
melanoma (Larson et al., 1983), ovarian carcinoma (Granow-
ska et al., 1984; Epenetos et al., 1985; Chatal et al., 1987)
and lung small cell carcinoma (Zimmer et al., 1985).
Non-small cell lung carcinomas (NSCLC), surprisingly, could
be visualised scintigraphically with McAbs not intended init-
iallly to react with them. Anti-CEA McAb (Riva et al., 1986),
anti-osteosarcoma (Perkins et al., 1986), an antibody directed
against c-myc oncogene product (Chan et al., 1986) and
Fab'2 fragments directed against hepatitis virus (Kalofonos
et al., 1988) have been used successfully to this end. In the
present work, the first purpose was to determine whether
Po66, a McAb prepared by immunisation against lung squa-
mous cell carcinoma (LSqCC) (Dazord et al., 1987), was
more effective than an unrelated immunoglobulin for
NSCLC imaging. The second objective was to evaluate the
value of immunoscintigraphy (IS) among other investigative
means in the diagnosis of NSCLC.
Material, patients and methods
Monoclonal antibody and radiolabelling procedure
Po66, an IgGI McAb, immunoprecipitated a 47 kDa mole-
cular weight antigen and was prepared as reported earlier
(Dazord et al., 1987). Briefly, Balb/c mice were immunised
with enzymatically dissociated cells from a patient's LSqCC.
Mouse immune cells were fused with SP2/0 plasmocytoma
and McAb Po66 was selected from the hybrids obtained.
Po66 consistently reacted with LSqCC, with half the adeno-
carcinomas tested and not with small cell lung carcinoma. It
did not recognise normal tissues except distal renal tubules
and gastric or bronchial serous glands (Dazord et al., 1987).
The Po66 batch designed for human use was purified from
ascites obtained from i.p. grafted Balb/c mice. The ascitic
fluid was precipitated in 40% saturation ammonium sul-
phate, dialysed against 10 mM, pH 8, phosphate buffer and
eluted through a DEAE ion-exchange column with a
10- 150 mM, pH 8, phosphate buffer gradient. The antibody
was subjected to the controls recommended by the European
Commission (Commission of the European Community,
Drafting Group Biotech/Pharmacy, 1986). A mouse IgGI
monoclonal immunoglobulin, Py, without known specificity,
was taken as control and processed like Po66. Samples of the
antibodies Po66 and Py were respectively radio-iodinated
with iodine-131 or iodine-125 by the iodogen method (Fraker
& Spek, 1978) and purified from free iodine by elution
through a Dowex anionic exchanger column equilibrated
with PBS containing 0.3% human serum albumin. The pro-
tein bound radioactive fraction averaged 90%. Each new
preparation of iodine-131 labelled Po66 was tested against
lung cancer cells using a competitive radioimmunoassay with
unlabelled antibody and the ability to accumulate into
tumours was checked in xenografted nude mice.
Selection and monitoring ofpatients
After the patients had given informed consent, 29 males and
one female, ranging from 42 to 77 years, were selected for the
trial. The diagnosis of malignancy was histologically estab-
lished by endoscopic bronchus biopsy. All patients had a
conventional plain chest X-ray and a thoracic CT scan when
required to determine eligibility for surgery. Immunoscinti-
graphy (IS) with Po66 was performed in 27 patients with
primary bronchial carcinoma (26 LSqCCs and one adenocar-
cinoma) and in six patients with recurrent tumour. More-
over, three distant metastatic localisations were investigated.
Fifteen of the 27 patients explored for primary tumour were
operated upon and 10 of them had a CT scan. In the patients
operated upon, the reactivity of Po66 with the tumour was
evaluated by peroxidase staining on deep frozen surgical
specimen as described previously. Radiolabelled Po66 was
administered to the patients after blocking thyroid and stom-
ach radioiodine uptake by ingestion of 1 g potassium iodide
and 0.5 g potassium perchlorate, 1 h before injection of the
antibody and daily throughout the 12 days of scintigraphic
exploration. There was no premedication against a possible
allergic effect. The radiolabelled antibody was diluted in
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150 ml of isotonic solution and infused intravenously over a
period of 45 mn. Each patient received I mg of intact anti-
body labelled with 70 MBq iodine-131.
Imaging
Thirty-three IS were performed using a large field of view
gamma-camera (Acti CGR) fitted with a high energy parallel
hole collimator and 128 x 128 word-mode computer storage
(MDS A2). Planar chest images of 15min each were per-
formed on days 3, 6, 9 and 12 after administration of McAbs
and additional images were done when necessary. 99Tcm-
labelled macroaggregates were delivered siinultaneously to
outline the lungs. Image subtraction procedures were used
only to improve the contrast and in all cases diagnosis was
made on the basis of presubtraction images.
Biodistribution
To study the distribution of antibody Po66, seven patients
received 1 mg of non-specific antibody Py labelled with
7 MBq of iodine-125 together with '31I-labelled Po66.
Radioactivity counting was made on three different samples
of blood and of various tissues: tumour, normal lung, muscle
and bone. A double isotope counting for '3'I and 1251 was
achieved. 131I radioactivity was counted directly from a pre-
determined window while, for 125, the contribution of '3'I in
the 1251 window had to be subtracted. The results were ex-
pressed in MBq per gram of tissue. A specific localisation
index (SLI) was calculated as follows:
tissue "' I x blood 1251
SLI =
21 11 tissue 125x X blood '3'I
Results
Saf, ty'
The injection was well tolerated by all patients and no
immediate or delayed adverse reaction occurred except in one
case of moderate and transient blood pressure fall without
loss of consciousness.
In vivo distribution
To assess the immunological specificity of the tumoral acc-
umulation of Po66, seven patients received 31I-labelled Po66
together with '251I-labelled Py, a non-related IgG I immuno-
globulin. Surgical specimens were sampled 6 days after i.v.
injection of both antibodies. The specific localisation indices
(SLI) are shown in Figure I and Table I.
SLI in tumour was always above 1 (1.40-5.67, mean 3.17)
and was significantly higher than the SLI found in healthy
lung (0.60- 1.89, mean 1.11) and in other tissues (0.32-2.00,
mean 1.07). The ratio of '"'I uptake in tumour as related to
healthy lung varied from 1.49 to 5.84 (mean 3.05).
Table I Specific localisation index in various organs andlungtumour/
non-tumoral lung tissue radioactivity uptake ratio (lung T/NT)
Specific localisation index
Patients Tumour Healthy lung Muscle Bone Lung TINT
1 4.25 1.04 1.16 1.20 4.08
2 5.67 0.97 0.57 0.98 5.84
3 4.00 1.38 1.17 1.67 2.90
4 1.37 0.90 1.90 2.00 1.52
5 2.19 0.60 1.90 0.60 3.65
6 2.80 1.89 1.17 1.34 1.49
7 1.95 1.02 1.03 0.32 1.91
The comparison of ISs performed in the same patients 3, 6,
9 and 12 days after Po66 injection showed that vascular
radioactivity declined more rapidly than tumour bound
radioactivity (Figure 2b). The cardiac image, indeed, was
constantly apparent on day 3 and decreased in the following
days until complete disappearance on day 12. Thus, tumours,
especially those located in the mediastinum area, were more
easily evidenced at later than at early intervals after admini-
stration of McAb. Kidney and liver were never detectable
scintigraphically after 6 days.
Comparison ofimmunoscintigraphy data with other
investigations
Tables II and III show the results of the 33 immunoscinti-
graphic investigations performed and other related data.
Table It refers to patients with primary chest tumour and
Table III to patients in recurrence. All patients had his-
tologically proven carcinoma as shown by endoscopic biopsy
and 15 of them were surgically confirmed. As can be seen in
Table II, 20 out of 27 primary cancers were visualised by
Figure 1 Localisation index in various organs of seven different
patients. 0, tumour; *, healthy lung; 0, muscle; 0, bone.
Figure 2 Recurrence 18 months after left pneumectomy for lung
carcinoma. a, Chest X-ray, anterior view. No tumour evidenced
in the right upper lobe by this technique. b, Immunoscintigraphy
(IS), anterior view: 3 days (A/) and 6 days (B/) after i.v. injection
of radiolabelled Po66. A complete disappearance of blood ac-
tivity between day 3 and day 6 was observed whereas tumour
labelling remained elevated. Note the uptake of 1311 by thyroid
gland.
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Table II Comparison of various clinical data with immunoscintography in patients with primary tumour
Antigen Size
No. X-ray Endoscopy CT-scan Scintigraphy Surgery detection (cm)
I RUL RULL n.d. normal pneumonectomy -
2 RLL RLL RLL normal pneumonectomy -
3 RLL RLL RLL normal lobectomy + 1 cm
4 normal LLL n.d. normal lobectomy + 2 cm
5 LH Left lung n.d. right lung n.d. n.d.
6 LH LH LH RH pneumonectomy +
7 RLL,RH RUL,RH n.d. LH,M n.d. n.d.
8 RUL,RH RUL RUL RUL,RH,M,LH pneumonectomy +
9 RUL,RH RUL,RH RUL,M RUL,M,LLL n.d. n.d.
10 RLL RLL,RML RLL RLL pneumonectomy + 7 cm
11 RUL RUL RUL RUL lobectomy + 1.5 cm
12 LLL,LH LLL,M n.d. LLL pneumonectomy +
13 RUL RUL,RH RUL,RH RUL,RH n.d. n.d.
14 LLL LLL LLL LLL pneumonectomy + 4 cm
15 LH LH n.d. LH n.d. n.d.
16 LLL,LH LUL,LLL LLL,LH LUL,LLL,LH n.d. n.d.
17 LLL LLL LLL LLL lobectomy + 4 cm
18 RUL RUL RUL RUL lobectomy + 2 cm
19 LUL LUL LUL LUL,M lobectomy +
20 LUL LUL n.d. LUL lobectomy + 7 cm
21 RUL,LH RUL,RH RH RH,M n.d. n.d.
22 RUL RUL RUL,RH RH n.d. n.d.
23 RH RH n.d. RLL,RH n.d. n.d.
24 RUL normal n.d. RH lobectomy +
25 RLL RLL n.d. RH n.d. n.d.
26 LUL,LH LUL,LLL n.d. LUL n.d. n.d.
27 LUL LUL n.d. LUL n.d. n.d.
M, mediastinum; RUL, right upper lobe; RLL, right lower lobe; LUL, left upper lobe; RH, right hilum; RML,
right median lobe; LH, left hilum; LLL, left lowerlobe; n.d., notdone. In addition to primary tumourpatient 25 had
a brain metastasis, patient 26 a skin metastasis and patient 27 a femur metastasis.
Table III Comparison of various clinical data with immunoscintigraphy in patients in
recurrence
No. X-ray Endoscopy CT-scan Scintigraphy First surgery
28(1) LUL LUL LUL LUL right pneumectomy
29(2) normal normal left lung left lung right pneumectomy
30(14) normal LUL RH,LUL RH,LUL right pneumectomy
31 normal n.d. right lung right lung left pneumectomy
32 RUL,RHnormal right lung right lung left pneumectomy
33 normal normal RLL,RH,LH RLL,RH,LH left pneumectomy
M, mediastinum; RUL, right upper lobe; RLL, right lower lobe; LUL, left upper lobe; RH,
right hilum; RML, right median lobe; LH, left hilum; LLL, left lower lobe; n.d., not done.
scintigraphic imaging as shown in Figure 3 and all six
patients with recurrent tumour had a positive IS (Table III).
Thus, the overall sensitivity of IS, as defined by the percen-
tage of known tumours detectable by this method of inves-
tigation, was 78%.
In seven instances, IS did not allow any visualization of
radiologically present tumours. In two cases (patients 1 and
2) the Po66-associated antigen could not be detected by the
immunoperoxidase technique performed on a surgical sam-
ple. In two cases (patients 3 and 4), the surgery report
indicated tumour size under 2cm in diameter. In the last
three cases (patients 5, 6 and 7), paradoxical results were
obtained: the tumour seen radiologically was not visualised
by IS but an intense McAb uptake occurred in the cont-
ralateral field (Figure 4). An important defect of vascularisa-
tion of the tumour, as judged from scintigraphy with 9"Tcm
labelled macroaggregates, was noticed in these patients, sug-
gesting that poor tumour vascularisation constitutes a limita-
tion to IS. Patient 6 was operated upon and a significant
mediastinal and contralateral involvement was found. The
other two patients had no anatomical control but they died
from severe respiratory failure within the 3 months following
surgery.
In patients 8, 9, 16 and 19, IS showed lesions of greater
extension than expected from radiological data (Figure Sa
and b). In patient 16 the involvement of left upper lobe
detected by IS but not by radiological means had been
noticed in the endoscopic examination. In patients 9 and 19,
the extension was confirmed by CT scan 3 months after IS.
In patient 8, surgery showed that the contralateral and med-
iastinal involvement corresponded to widespread small tu-
moral granulations.
In the patients of Table III, IS was done as a systematic
investigation 4-6 months after initial surgery. Six local
relapses were discovered by IS while conventional chest X-
ray in four cases and endoscopic examination in three cases
did not allow any tumour detection (Figure 2a and b). The
tumour localisations evidenced by IS were confirmed later by
CT scan in all patients.
Discussion
The present clinical trial showed the ability of McAb Po66 to
visualise non-small cell lung carcinoma (NSCLC) with a 78%
sensitivity. These results confirm the work by Kalofonos et
al. (1988) showing, in a series of 14 patients, that NSCLC
could be easily detected using a F(ab')2 fragment directed
against human milk fat globules and reacting histologically
with the tumours. These authors, like others (see Introduc-
tion), showed that NSCLC could be non-specifically visual-
ised by unrelated antibodies. The non-specific retention of
circulating proteins or macromolecules in cancer has been
documented and seems related to the particularities of vas-
culature of tumours (Jain, 1987; O'Connor & Bale 1984). In
our own study, the SLI measurements performed showedPo66 AND LUNG-SQUAMOUS CELL CARCINOMA 233
Figure 3 Lung carcinoma of right upper lobe. a, Chest X-ray,
anterior view. b, IS of the same patient 6 days after injection of
radiolabelled Po66; anterior view showing the tumour and car-
diac image.
Figure 4 Patient with lung carcinoma of left hilum. IS with
Po66, anterior view (left) showed an antibody uptake in the right
field while the left hilum tumour could not be detected. Scan with
'Tcm labelled microaggregates (right) showed the poor vascu-
larisation of left hilum.
that McAb Po66 raised against an LSqCC bound three times
more to the tumours than an unrelated immunoglQbulin.
This observation confirms comparable investigations by Kal-
ofonos et al. (1988) and shows very clearly that McAbs
specially intended to react with tumour should be prefered to
unrelated proteins. Interestingly, the mean SLI value with
Po66 in humans was of 3.2 and did not differ significantly
from the 3.4 result obtained with xenografted tumours in
mouse (Dazord et al., 1987), although most studies show a
decrease of SLI in humans when compared to animal studies.
The main problem concerning IS of lung cancer is its place
among other tools of investigation. Lung cancers are partic-
Figure 5 Patient no. 8. a, Chest X-ray. Lung carcinoma radio-
logically limited to the right upper lobe. b, IS, anterior view,
showing an intense uptake of the monoclonal antibody in the
mediastinum and a diffuse uptake in the two lung fields. Surgical
control showed that the contralateral and mediastinal involve-
ment corresponded to widespread small tumoral granulations.
ularily accessible to radiological investigations and the in-
terest of IS might appear relatively restricted. In fact, in our
short series of 33 patients, IS gave information not given by
other means of investigation in at least eight instances. In
four patients at the preoperative stage (nos 8,9,16 and 19), IS
showed lesions more extended than those detected by CT-
scan and there was some evidence that these scintigraphic
abnormalities corresponded to real tumour involvements.
The possibility that the lesions corresponded to disseminated
small tumours was suggested in one case. Likewise, in the
patient with recurrent tumour, IS detected lesions not evi-
denced by plain chest X-ray in four of the six patients
investigated.
Although the present prospective study is still in progress,
an attempt can be made to define the role of IS in the
follow-up of LSqCC patients. It seems obvious that IS can-
not be used for the initial diagnosis which is done by clinical
examination, plain chest X-ray and especially by endoscopic
biopsy. We infer, however, that IS may be helpful to evaluate
the extension of the lesions discovered. Possible mediastinal
and contralateral involvement, which contraindicate surgery,
might be assesed by IS. Furthermore, IS seems valuable in
those patients who have been operated upon and in whom
recurrence is suspected.
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